Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

LONDON, Nov 7 — Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar ...

Osteoarthritis of the knee is a common and often painful condition affecting millions worldwide, especially older adults. As ...

Another trend Srinivasa expects to see in 2025 is more skin-tightening procedures, following the growing popularity of weight loss drugs such as Wegovy.

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

For Sprackling, the key to consumers benefiting from GLP-1 medications is responsible use rather than viewing them as a quick ...

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs ...

A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose ...

Chances are you have family or friends who have struggled with weight loss for years, losing weight on the latest ... "We don't yet know all the long-term side effects as this is a new trend among non ...

Novo Nordisk (NVO) posts Q3 sales for its weight loss drug Wegovy, contrasting rival Eli Lilly's (LLY) quarterly miss for its obesity drug, Zepbound. Read more here.

Ozempic sales were a bit lower than expected in the quarter at DKK 29.8 billion, while Wegovy sales were higher at DKK 17.3 ...